ArticleACS applied materials & interfaces2025
Fluorescent Molecular Probe for Imaging Hypoxia in 2D Cell Culture Monolayers and 3D Tumor Spheroids: The Cell Membrane Partition Model for Predicting Probe Distribution in a Spheroid.
Article in ACS applied materials & interfaces, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Three-dimensional spheroid models in breast cancer: tumor microenvironment complexity, cancer stem cell-driven resistance, and translational model integration.Journal of translational medicine · 2026Review
- Annulated cationic tetramethyl indo(di)carbocyanine dyes exhibit potent dark cytotoxicity in cancer cells.Dyes and pigments : an international journal · 2026Article
- Dual Epigenetic and Chaperone Inhibition Disrupts Hypoxia Signaling and Tumor Progression in 3-D Models of Triple-Negative Breast Cancer.Research square · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Compared to cultured 2D cell monolayers, 3D multicellular spheroids are more realistic tumor models. Nonetheless, spheroids remain under-utilized in preclinical research, in part, because there is a lack of fluorescence sensors that can noninvasively interrogate all the individual cells within a spheroid. This present study describes a deep-red fluorogenic molecular probe for microscopic imaging of cells that contain a high level of nitroreductase enzyme activity as a biomarker of cell hypoxia. A first-generation version of the probe produced "turn-on" fluorescence in a 2D cell monolayer under hypoxic conditions; however, it was not useful in a 3D multicellular tumor spheroid because it only accumulated in the peripheral cells. To guide the probe structural optimization process, an intuitive theoretical membrane partition model was conceived to predict how a dosed probe will distribute within a 3D spheroid. The model identifies three limiting molecular diffusion pathways that are determined by a probe's membrane partition properties. A lipophilic probe with high membrane affinity rapidly becomes trapped in the membranes of the peripheral cells. In contrast, a very hydrophilic probe molecule with negligible membrane affinity diffuses rapidly through the spheroid intercellular space and rarely enters the cells. However, a probe molecule with intermediate membrane affinity undergoes sequential diffusion in and out of cells and distributes to all the cells within a spheroid. Using the model as a predictive tool, a second-generation fluorescent probe was prepared with a smaller and more hydrophilic molecular structure, and optical sectioning using structured illumination or light sheet microscopy revealed roughly even probe diffusion throughout a tumor spheroid. The membrane permeation model is likely to be broadly applicable for the structural optimization of various classes of molecules and nanoparticles to enable even distribution within a tumor spheroid.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.